Megadeals Are Back. Here’s Why J-P Conte Thinks Patient Capital Still Wins.

US private equity deal value rose about 8% year over year in the first half of 2025 to just over $195 billion, and US-based PE dry powder dropped from a December 2024 peak of $1.3 trillion to roughly $880 billion by September, PwC reported in its 2026 private equity outlook. The capital is moving, and most of it is moving into a small number of very large transactions. For J-P Conte and his family office Lupine Crest Capital, that concentration is the most important feature of the 2026 deal market, and the one that makes patient capital more valuable than it’s been in years.

The Big Deals Are Crowded

Megadeal activity has come back faster than the broader market. PwC counted 47 megadeals valued at $5 billion or more through the first nine months of 2025, putting the year on pace to finish 31% above 2024’s megadeal count and 17% above last year’s large-deal total, per the firm’s September 2025 deals analysis. Industrial manufacturing specifically saw transactions above $5 billion account for 52% of total deal value in 2025, up from just 18% in FY24 when only one megadeal closed in the sector, per PwC’s industrial manufacturing 2026 outlook. The bid sheets at the top of the market are full.

The buyer pool has also concentrated. Large diversified asset managers are taking a growing share of total commitments, with limited partners backing fewer firms and demanding more demonstrated value creation discipline from the ones they back. PwC describes the dynamic plainly: more sponsors are chasing fewer high-quality assets, while sovereign wealth funds and family offices continue to expand their presence on the back of patient capital and lower-debt structures. That observation is what’s actually shaping the 2026 deal market.

Megadeal competition has consequences below the headline figures. Mid-sized sponsors are losing assets they would have won in 2021. Some are taken by larger PE platforms with continuation vehicle capacity. Others are won by family offices like J-P Conte’s that can move faster on operating asset due diligence without committee approval. The competition for the next tier of assets is being intensified by the same forces.

Why Patient Capital Beats Fund-Stage Capital

The structural advantage of patient capital isn’t new. What’s changed is the price the rest of the market is paying to operate without it. Fund-stage sponsors are bound by hard exit windows, LP redemption pressure, and IRR targets that compound the cost of every quarter a portfolio company sits unsold. Family offices with permanent capital and no external committee approval are not constrained the same way. The same target asset is worth more to a family office than to a sponsor because the family office isn’t pricing in the cost of an exit by year five.

The PwC PE outlook makes the consequence explicit: family offices and sovereign wealth pools are expanding their footprint while sponsor fundraising slows. Global PE fundraising fell to about $150 billion in Q2 2025, down slightly from Q1, and commitments to traditional commingled funds dropped about 24% year over year. US fundraising specifically is tracking roughly 40% below the prior year. The marginal dollar that would have flowed to a mid-market PE fund five years ago is now going somewhere else, and family offices are one of the largest recipient categories.

Bain & Company describes the broader pattern in its 2026 private equity report, Outlook: Gaining Traction, as deal and exit value surging in a narrow recovery powered by megadeals. Recovery that depends on a small number of very large transactions is a recovery that’s vulnerable to the next macro shock. Patient capital structures are designed to perform without requiring that recovery to keep widening.

The pricing pressure created by megadeal competition compresses the equity returns available to fund-stage sponsors. That compression doesn’t apply the same way to a family office balance sheet, because the family office isn’t underwriting against a fund-level IRR target.

J-P Conte’s Operating Model in This Environment

Lupine Crest Capital invests across private equity, real estate, and venture, with a middle-market focus on healthcare, financial services, software, and industrial technology. The structure makes the most of the 2026 dealmaking environment in three ways.

First, the firm doesn’t have to compete for the megadeal trophy assets. Lupine Crest’s deal envelope is set below the level where sovereign wealth funds and continuation vehicles dominate the auction. That keeps the firm out of the most overpriced segment of the market by design.

Second, the firm can underwrite at its own pace. Sponsor-led deals run on 60-to-90-day timelines that are set by the lender’s diligence cycle and the sponsor’s exit timetable. A family office doesn’t face the same constraints. Conte can spend the time required to actually understand an asset, run reference calls without rushing the seller, and walk away from deals that don’t meet conservative underwriting standards.

Third, the firm’s hold period isn’t bounded by fund life. PwC notes that PE firms are still holding companies that committed capital in 2017 and 2018, with the median age of exited companies in H1 2025 sitting around six years and the broader inventory aging beyond pre-pandemic norms. Family offices that bought at the same vintage simply held longer and aren’t selling under pressure. That hold flexibility is a value source the megadeal acquirers can’t replicate without taking on the same LP obligations they’re trying to escape.

The deal-side advantage is the easier part to describe. The harder part is the seller-side advantage that patient capital creates over a multi-year hold. J-P Conte’s track record across multiple capital cycles, the long sector tenure of his team at Lupine Crest, and the discipline of holding through dislocation rather than around it are what make sellers prefer a family office bid over a sponsor bid when execution certainty matters more than headline price. Sellers know which buyers actually close.

Megadeals are back. The narrow recovery PwC and Bain describe is real, and so are the equity returns available at the top of the market for the firms that can compete there. Those returns exist, and patient capital doesn’t deny them. The argument runs the other way: the rest of the market, the middle market where Conte’s family office actually operates, is where patient capital makes the most economic difference, and where the structural advantages of his model produce returns that don’t require the megadeal cycle to keep widening.